Table 2.

Effects of restoration of wild type Ompk35 and Ompk36 into clinical KPC-KP isolates

Strain	Description	MIC (mg/L)
		CZA	CAZ	IMP	MEM	ATM	FEP
8A	clinical isolate 8A	8	≥64	≥16	≥16	≥64	≥32
KPM30	8A + Blunt vector	4	≥64	≥16	≥16	≥64	≥32
KPM02	8A + Blunt::ompk35_wt	4	≥64	≥16	≥16	16	≥32
KPM06	8A + Blunt::ompk36_wt	8	≥64	≥16	≥16	≥64	≥32
1B	clinical isolate 1B	2048	≥64	1	4	≥64	≥32
KPM21	1B + Blunt vector	2048	≥64	0.5	4	≥64	≥32
KPM10	1B + Blunt::ompk35_wt	2048	≥64	1	≤0.25	≥64	≥32
KPM11	1B + Blunt::ompk36_wt	2048	≥64	0.5	0.5	≥64	≥32
3B	clinical isolate 3B	512	≥64	≥16	≥16	≥64	≥32
KPM23	3B + Blunt vector	512	≥64	≥16	≥16	≥64	≥32
KPM01	3B + Blunt::ompk35_wt	512	≥64	≥16	≥16	≥64	≥32
KPM05	3B + Blunt::ompk36_wt	512	≥64	≥16	≥16	≥64	≥32
7B	clinical isolate 7B	512	≥64	2	2	≥64	≥32
KPM27	7B + Blunt vector	512	≥64	2	2	≥64	≥32
KPM04	7B + Blunt::ompk35_wt	512	≥64	1	2	≥64	≥32
KPM08	7B + Blunt::ompk36_wt	512	≥64	1	2	≥64	≥32
8B	clinical isolate 8B	256	≥64	2	4	≥64	≥32
KPM28	8B + Blunt vector	256	≥64	1	4	≥64	≥32
KPM03	8B + Blunt::ompk35_wt	256	≥64	2	0.5	16	2
KPM07	8B + Blunt::ompk36_wt	256	≥64	1	4	≥64	≥32

Abbreviations: CZA ceftazidime/avibactam; CAZ ceftazidime; IMP imipenem; MEM meropenem; ATM aztreonam; FEP cefepime